NCT06084689 2025-09-02
EMPIRE
Institut Bergonié
Phase 2 Withdrawn
Clinical Trials
13 trialsNCT04571710 2025-07-24
A Trial of SHR1258 in Patients With Biliary Tract Cancer
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Withdrawn
NCT06017297 2024-11-12
ESR-22-21719
Georgetown University
Phase 2 Withdrawn
NCT03999658 2023-05-01
A Study of STI-3031 (an Anti-PD-L1 Antibody) in Patients With Selected Relapsed/Refractory Malignancies
Sorrento Therapeutics, Inc.
Phase 2 Withdrawn
NCT05041972 2022-09-13
ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)
Ambrx, Inc.
Phase 2 Withdrawn
NCT03110510 2022-06-15
FOLFIRI as Salvage Treatment in Metastatic Biliary Tract Cancer (BTC) Patients Who Were Failed After Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study
Samsung Medical Center
Phase 2 Withdrawn
NCT04796454 2022-06-01
PAMICC
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Withdrawn
NCT04480190 2022-04-20
Neoadjuvant Therapy in Biliary Adenocarcinoma
University of Cincinnati
Phase 1 Withdrawn
NCT03419247 2021-04-01
Molecular Profiling of Advanced Biliary Tract Cancers
University Health Network, Toronto
Phase NA Withdrawn
NCT04186156 2021-02-03
A Study of Selective HDAC6 Inhibition With KA2507 in Advanced Biliary Tract Cancer
Karus Therapeutics Limited
Phase 2 Withdrawn
NCT03129074 2018-05-23
Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer
ASLAN Pharmaceuticals
Phase 2 Withdrawn
NCT02720601 2018-01-25
Irinotecan and Capecitabine as Second-line Treatment for Advanced/Metastatic Biliary Tract Cancers
New Mexico Cancer Research Alliance
Phase 2 Withdrawn
NCT00487851 2013-04-12
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Karolinska Institutet
Phase 2 Withdrawn